The new anti-hypertension drug “Allisartan and Amlodipine tablets” (FoLitan®) approved for market

Publisher: Views:

Good news

Recently, Salubris announced that the new anti-hypertension drug “Allisartan and Amlodipine tablets” (FoLitan®) had obtained the drug registration certificate issued by NMPA.

Allisartan and Amlodipine tablets (FoLitan®), a domestic original ARB/CCB compound preparation(Project code: SAL0107), is used for the treatment of essential hypertension, indicated for adult patients with poor blood pressure control treated with Allisartan Isoproxil alone or Amlodipine alone.

Allisartan and Amlodipine tablets (FoLitan®) have classic components, high reliability, and well-proven antihypertensive efficacy. After the launch of the product, it will be targeting hypertension patients in varied segments, and form strategic synergy with Salubris’ listed class 1 innovative drug Xinlitan (Allisartan Isoproxil tablets) in multiple channels, enriching the innovative product pipeline in the field of hypertension, and enhance Salubris’ comprehensive competitiveness in the field of chronic disease.


General information of drug registration certificate

· Generic name: Allisartan and Amlodipine tablets

· Dosage forms: tablet

· Strengths: Allisartan Isoproxil 240mg and Amlodipine besylate (as measured by amlodipine) 5mg tablets

· Registration classification: Chemical 2.3

· Drug approval number: 国药准H20240016